Dermatitis
MONDO:0002406An inflammatory process affecting the skin. Signs include red rash, itching, and blister formation. Representative examples are contact dermatitis, atopic dermatitis, and seborrheic dermatitis.
Also known as: inflammation of skin, inflammation of the skin, inflammation of zone of skin, inflammatory skin disease, skin inflammation, zone of skin inflammation
1411 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 430 trials in this tab.
-
Can the MenB vaccine protect kids with rheumatic conditions?
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing the meningococcal B vaccine (Bexsero) in children and young adults aged 2 to 25 who have autoimmune rheumatic diseases like juvenile arthritis or lupus. Researchers want to see if the vaccine triggers a strong immune response and if it is safe, especially fo…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:10 UTC
-
New vaccine trial aims to shield vulnerable children from pneumonia
⭐️ VACCINE ⭐️ Recruiting nowThis study tests the safety and immune response of the 20-valent pneumococcal vaccine (PCV20) in children, adolescents, and young adults aged 2-25 with autoimmune rheumatic diseases like juvenile arthritis. All 114 participants will receive one dose of PCV20, and researchers will…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:11 UTC
-
Could a histamine shot tame chronic hives?
Disease control Recruiting nowThis study looks at how well an injection called Immunoglobulin-Histamine complex (IHC, brand name Histoglob) works for people with chronic urticaria, or long-term hives. Researchers will track 600 patients in India to see if the treatment reduces hives and the need for other all…
Sponsor: Bharat Serums and Vaccines Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase: PHASE2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Friendly bacteria gel could tame eczema flares
Disease control Recruiting nowThis early-stage trial is testing whether a gel containing beneficial bacteria (Staphylococcus hominis A9) can safely control eczema flares. About 86 adults and children aged 6 and older will apply the gel or a placebo twice daily for 14 weeks, along with a short course of steroi…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at blistering skin disease
Disease control Recruiting nowThis study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are tho…
Phase: NA • Sponsor: Jinbo Chen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New shot offers hope for Tough-to-Treat eczema
Disease control Recruiting nowThis study tests an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe eczema that hasn't improved with other treatments. Participants will also use standard steroid creams. The goal is to see if the drug can clear or nearly clear the skin com…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New shot may stop hives from cold and scratching
Disease control Recruiting nowThis study tests an investigational drug called barzolvolimab in 240 adults who get hives from cold temperatures or from scratching their skin, and whose symptoms are not controlled by standard allergy pills. Participants receive either the drug or a placebo injection, and doctor…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can supplements boost healing after gum color surgery?
Disease control Recruiting nowThis study looks at whether taking coenzyme Q10 and vitamin C, alone or together, can improve healing and reduce dark gum color after surgical gum depigmentation. The trial involves 20 healthy adults with dark gums who undergo a simple scalpel procedure to remove pigmented tissue…
Phase: NA • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control Recruiting nowThis study is for people with moderate-to-severe eczema who have already completed a previous APG777 trial. It aims to see if APG777 is safe and works well over a longer period. Participants will receive injections of the drug every 12 or 24 weeks and be monitored for side effect…
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowThis phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill RAP-103 aims to clear psoriasis in 8 weeks
Disease control Recruiting nowThis Phase 2 trial tests whether the oral drug RAP-103 can improve skin clearance and quality of life in people with moderate to severe psoriasis. About 90 adults aged 18 to 70 will take either a daily or twice-daily dose of RAP-103 or a placebo for 8 weeks. The study measures ho…
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New oral pill aims to clear psoriasis in major trial
Disease control Recruiting nowThis phase 3 study tests whether the experimental drug WD-890 can safely improve skin clearance in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either WD-890 or a placebo tablet daily for up to 52 weeks. The main goals are to see …
Phase: PHASE3 • Sponsor: Zhejiang Wenda Pharma Technology LTD. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could stop and treat dangerous swelling attacks
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, a…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowThis study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …
Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Psoriasis drug risankizumab under Real-World spotlight for quality of life boost
Disease control Recruiting nowThis study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for eczema sufferers: drug switch trial launches
Disease control Recruiting nowThis study tests whether upadacitinib, an oral tablet, can help adults with moderate to severe eczema (atopic dermatitis) who didn't get enough relief from dupilumab injections. About 200 participants will be randomly assigned to take upadacitinib or continue dupilumab for 8 week…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New eczema drug enters first human trials
Disease control Recruiting nowThis study is the first time REGN20423 is being tested in humans. It will enroll 144 adults, first healthy volunteers and then people with atopic dermatitis (eczema). The goal is to check safety, side effects, how the drug moves through the body, and whether it helps eczema sympt…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug AZD5492 tested for autoimmune diseases in first human study
Disease control Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot could tame severe eczema in kids as young as 6 months
Disease control Recruiting nowThis study tests whether a drug called tralokinumab, given as a shot along with steroid cream, can safely control moderate-to-severe eczema in children aged 6 months to under 12 years. About 195 participants will receive either the drug or a placebo for 16 weeks, then all will ge…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot aims to recolor white patches in vitiligo
Disease control Recruiting nowThis study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for vitiligo: experimental drug aims to bring back skin color
Disease control Recruiting nowThis study tests an experimental drug called GIA632 in 210 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the drug can safely restore skin color and to find the best dose for future studies. Participants will receive e…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for painful hand and foot pustules: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug bimekizumab can clear or nearly clear the pustules and skin lesions of palmoplantar pustulosis (PPP) on the hands and feet. About 320 adults with moderate to severe PPP will receive either bimekizumab or a placebo for 16 weeks, with an op…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill could clear psoriasis skin in 12 weeks
Disease control Recruiting nowThis Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% imp…
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for rare, painful skin condition: drug trial underway
Disease control Recruiting nowThis study tests if guselkumab can help people with Hailey-Hailey disease, a genetic condition causing painful blisters and sores in skin folds. Ten adults with moderate to severe disease will receive the drug and be monitored for changes in skin severity and quality of life. The…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…
Phase: PHASE2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Real-World data to show if HAE drug works in kids
Disease control Recruiting nowThis study tracks 40 children aged 2 to 12 with hereditary angioedema (HAE) who are taking lanadelumab to prevent sudden, painful swelling attacks. Researchers will look at medical records to see how long kids stay attack-free and how the drug performs in daily life. No new treat…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could clear psoriasis in teens
Disease control Recruiting nowThis study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could clear skin in kids with psoriasis – trial underway
Disease control Recruiting nowThis phase 3 trial tests whether zasocitinib, an oral medication, can safely and effectively treat moderate-to-severe plaque psoriasis in children and teens aged 4 to 17. The study involves 110 participants and lasts up to 4 years. In the first part, some receive the drug and oth…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shot could tame tough eczema
Disease control Recruiting nowThis study tests a drug called FB825 in adults with moderate-to-severe atopic dermatitis (eczema). Participants receive five injections over 12 weeks, either FB825 or a placebo, to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment opti…
Phase: PHASE2 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New psoriasis drug faces off against standard treatment in massive Heart-Safety trial
Disease control Recruiting nowThis study tests the long-term safety of deucravacitinib compared to ustekinumab in about 3,040 adults with moderate-to-severe plaque psoriasis who also have heart risk factors like smoking, high blood pressure, or diabetes. Participants will receive one of the two medications an…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New RNA drug aims to stop debilitating swelling attacks in rare genetic condition
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called ADX-324 in 90 adults with hereditary angioedema (HAE) types 1 or 2. HAE causes sudden, painful swelling in the body. ADX-324 uses a technology called siRNA to lower levels of a protein involved in triggering these attacks.…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gel could tackle stubborn yeast infections
Disease control Recruiting nowThis study tests a new gel called OCF001 for treating acute yeast infections in women. About 36 women with a confirmed yeast infection will use the gel or a placebo for 7 days. Researchers will check if the infection clears up and if the gel is safe and well-tolerated.
Phase: PHASE2 • Sponsor: Sano Chemicals Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New eczema drug TRB-061 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called TRB-061 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study checks for safety, side effects, and how the drug moves through the body. Participants receive either TRB-061 or a placebo as injectio…
Phase: PHASE1 • Sponsor: TRex Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New RNA drug shows promise in preventing HAE attacks in ongoing study
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who have already completed a previous trial of the drug ADX-324. ADX-324 is an RNA-based medicine designed to lower a protein involved in swelling attacks. The goal is to see if long-term use is safe and can reduce the num…
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New eczema drug enters first human tests
Disease control Recruiting nowThis early-stage study tests a new drug called DCY636 for safety and tolerability in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The trial has two parts: a single dose in healthy adults and multiple doses in eczema patients. It aims to gather…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New shampoo regimen aims to soothe scalp after hair transplants
Disease control Recruiting nowThis study tests whether a special shampoo regimen can improve scalp health and reduce dandruff in 120 Chinese men who have had hair transplants. Some participants have mild-to-moderate seborrheic dermatitis (a common dandruff condition). The test group uses a special shampoo plu…
Phase: NA • Sponsor: ChinaNorm • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can a new pill bring back skin color in vitiligo?
Disease control Recruiting nowThis study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New psoriasis pill shows promise in major trial
Disease control Recruiting nowThis study tests an experimental drug called ponesimod in 300 adults with moderate-to-severe plaque psoriasis. The goal is to see if it is safe and helps control the disease. Participants take the drug and are monitored for side effects and skin improvement.
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot for eczema shows promise in large trial
Disease control Recruiting nowThis study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone …
Sponsor: Chengdu Kangnuoxing Biopharma,Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Psoriasis patients monitored for two years on newer biologic drug
Disease control Recruiting nowThis study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this trea…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Laser and steroid mouthwash aim to tame painful mouth sores in autoimmune disease
Disease control Recruiting nowThis study tests whether a steroid mouthwash (clobetasol propionate 0.05%) and low-level laser therapy, alone or together, can heal painful mouth sores in people with pemphigus vulgaris—a chronic autoimmune disease that causes blisters on skin and mucous membranes. Thirty partici…
Phase: NA • Sponsor: Damascus University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Eczema drug afimkibart tested for Long-Term safety in new study
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThis study tests a cream called delgocitinib for lichen sclerosus, a skin condition that causes itching, pain, and scarring in the genital area. About 652 adults with mild to severe disease will apply the cream twice daily for up to 52 weeks. Researchers will check if the cream i…
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill could help kids with severe psoriasis
Disease control Recruiting nowThis study tests a drug called deucravacitinib in children and teens aged 4 to 18 with moderate to severe plaque psoriasis. The trial will measure how the drug works in the body, how well it clears psoriasis, and its safety over up to 5 years. Participants are randomly assigned t…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a cream stop scarring hair loss? small trial begins
Disease control Recruiting nowThis pilot study tests a topical cream called delgocitinib in 30 adults with two types of scarring hair loss: lichen planopilaris and central centrifugal cicatricial alopecia. Participants apply the cream twice daily for 48 weeks. The study focuses on safety and changes in immune…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for teens with stubborn hives: drug trial launches
Disease control Recruiting nowThis study tests a drug called remibrutinib in teenagers aged 12 to 17 who have chronic spontaneous urticaria (hives that come and go for no clear reason) that isn't controlled by antihistamines. About 100 participants will receive either the drug or a placebo for 24 weeks, with …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo to see if it improves skin symptoms by at least 75% after 12 weeks. The goal is to control the diseas…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Small study to uncover how psoriasis drug tames the immune system
Disease control Recruiting nowThis study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune …
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug targets immune cells in scalp psoriasis
Disease control Recruiting nowThis study tests how guselkumab, a drug that blocks IL-23, affects immune cells in scalp psoriasis lesions. Ten adults with moderate-to-severe scalp psoriasis will receive treatment and have their scalp severity scores measured before and during treatment. The goal is to understa…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New psoriasis drug could be cheaper alternative to tremfya
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called QL2106 works as well as the approved medication Tremfya for people with moderate to severe plaque psoriasis. About 318 participants will receive either QL2106 or Tremfya injections over several months. The main goal is to se…
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Psoriasis drug trial aims to calm overactive immune cells
Disease control Recruiting nowThis study looks at how deucravacitinib, a drug that blocks a specific immune signal (TYK2), changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. About 25 adults will take the drug and be monitored for improvements in their psoriasis symptoms. T…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to restore skin color in vitiligo patients
Disease control Recruiting nowThis study tests whether a new drug called EI-001 can help people with vitiligo, a condition that causes white patches on the skin. The drug works by calming the immune system to reduce inflammation. About 45 adults with nonsegmental vitiligo will receive either EI-001 or a place…
Phase: PHASE2 • Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cream shows promise for painful hand and foot pustules
Disease control Recruiting nowThis study tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis, a skin condition causing painful pus-filled blisters on hands and feet. About 135 adults will apply the cream twice daily for 16 weeks. The main goal is to see if the cream reduce…
Phase: PHASE2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Boric acid inserts aim to cure yeast infections in new trial
Disease control Recruiting nowThis study tests whether boric acid vaginal inserts (600 mg) taken for 7 or 14 days can safely and effectively treat yeast infections. About 400 women aged 12 and older with active symptoms will participate. The goal is to see if all signs and symptoms disappear without needing m…
Phase: PHASE3 • Sponsor: pH-D Feminine Health LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New HAE drug garadacimab tested in real life: will it hold up?
Disease control Recruiting nowThis study follows 200 people with hereditary angioedema (HAE) who are starting garadacimab in routine medical care. Researchers will track how well the drug prevents swelling attacks, its safety, and its impact on quality of life over 48 months. The goal is to see if results fro…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can olive oil and nuts tame psoriasis? new study tests diet plus biologics
Disease control Recruiting nowThis study tests whether adding a Mediterranean diet (rich in olive oil, nuts, fish, and limited red meat) improves psoriasis symptoms in 36 adults who are about to start biologic therapy (Anti-IL-17 or Anti-IL-23 drugs). Participants are randomly assigned to either follow the di…
Phase: NA • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Weight-Loss drug tirzepatide could double as psoriasis treatment in new trial
Disease control Recruiting nowThis study is testing whether adding the weight-loss drug tirzepatide to the standard psoriasis medication ixekizumab helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 adults will receive tirzepatide injections for up to 12 months. …
Phase: PHASE4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill could tame stubborn hives
Disease control Recruiting nowThis study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug hopes to ease rare muscle diseases
Disease control Recruiting nowThis Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug S-4321 aims to tame overactive immune system
Disease control Recruiting nowThis early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…
Phase: PHASE1 • Sponsor: Seismic Therapeutic AU Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody aims to calm eczema Flare-Ups from the inside
Disease control Recruiting nowThis study tests an experimental drug called BFB759, a lab-made antibody that blocks several inflammatory signals at once. Researchers want to see if it can reduce redness, swelling, and itching in adults with moderate-to-severe eczema that hasn't improved with creams. About 225 …
Phase: PHASE2 • Sponsor: Bluefin Biomedicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowThis study tests two types of engineered immune cells (CAR T cells) in 40 adults with active pemphigus vulgaris, a painful blistering skin condition. The cells are designed to target and reduce the faulty immune cells that attack the skin. The main goal is to check safety and fin…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Natural prebiotic could beat antibiotics for thrush and BV
Disease control Recruiting nowThis study tests whether lactoferrin, a natural prebiotic from cow's milk, can be a good alternative to antibiotic tablets for women with bacterial vaginosis (BV) or thrush. Researchers will recruit 114 women and give half lactoferrin vaginal pessaries for 3 weeks, while the othe…
Phase: NA • Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Weekly shot aims to tame rare muscle diseases
Disease control Recruiting nowThis study tests anifrolumab, a weekly injection, for adults with moderate to severe polymyositis or dermatomyositis—rare diseases that cause muscle weakness and inflammation. About 240 participants will receive either anifrolumab or a placebo added to their usual care for 52 wee…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for kids with rare swelling disorder: early access drug offered
Disease control AVAILABLEThis program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children …
Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for kids with rare swelling disorder as drug trial begins
Disease control Recruiting nowThis study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Donor immune cells aim to tame autoimmune attacks
Disease control Recruiting nowThis early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…
Phase: PHASE2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New immune cell combo tackles tough autoimmune diseases
Disease control Recruiting nowThis phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …
Phase: PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New psoriasis drug shows promise for kids in Head-to-Head trial
Disease control Recruiting nowThis study tests a new medicine called bimekizumab against an existing one (ustekinumab) for children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if bimekizumab works better at clearing skin symptoms. About 168 participants will receive inj…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a stronger acne drug be better for darker skin? new trial aims to find out
Disease control Recruiting nowThis study compares giving oral isotretinoin (a strong acne medication) right away versus the usual antibiotics for moderate acne in people with darker skin (Fitzpatrick types IV-VI). The goal is to see if early use of isotretinoin reduces acne-related dark spots better than stan…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New biosimilar aims to rival blockbuster eczema drug
Disease control Recruiting nowThis early-stage trial tests whether a new drug called GS101 works like the approved eczema treatment Dupixent. Researchers will give a single shot to 294 healthy adults in China and compare how the drug moves through the body, its safety, and immune response. The goal is to see …
Phase: PHASE1 • Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a pill and light combo beat vitiligo?
Disease control Recruiting nowThis study tests whether taking a daily pill (ritlecitinib) plus twice-weekly narrowband UVB light therapy works better than the pill alone for vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much skin…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New psoriasis drug tracked in everyday patients
Disease control Recruiting nowThis study follows 350 adults in France with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will track how well the drug controls skin symptoms and improves quality of life over time in real-world settings, not a controlled lab env…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a Once-a-Week acne pill replace daily antibiotics?
Disease control Recruiting nowThis study compares a weekly dose of isotretinoin (a vitamin A derivative) to daily tetracycline antibiotics for treating moderate acne. Researchers want to see if the weekly approach works just as well, with fewer side effects and less reliance on antibiotics. The trial will enr…
Phase: EARLY_PHASE1 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New study tracks how well eczema drug works in real life for 1,000 patients in china
Disease control Recruiting nowThis study will follow about 1,000 adolescents and adults in China who are prescribed upadacitinib for moderate to severe atopic dermatitis (eczema). Researchers will track how patients use the medication, any dose changes, and how well they stick to their treatment over 12 month…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise for rare muscle diseases
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and rashes. Participants who completed a previous study can join. Some will receive the drug via IV every 4 weeks for abo…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug remibrutinib tested for chronic hives relief in Real-World study
Disease control Recruiting nowThis study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world ef…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Psoriasis patients switch biologics in new Real-World study
Disease control Recruiting nowThis study watches 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in everyday medical practice. Researchers track how well the new drug clears skin symptoms and check for side effects over 52 weeks. The goal is to see if guselkumab works sa…
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New daily pill could stop debilitating swelling attacks in HAE patients
Disease control Recruiting nowThis Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Battle of the bands: which hemorrhoid treatment wins?
Disease control Recruiting nowThis study compares two standard treatments for bleeding internal hemorrhoids: hemorrhoidal artery embolization (HAE) and rubber band ligation (RBL). HAE uses a catheter to block blood flow to the hemorrhoid with tiny particles or coils, while RBL uses rubber bands to cut off cir…
Phase: NA • Sponsor: Jessica K. Stewart, MD • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could an antidepressant boost psoriasis treatment?
Disease control Recruiting nowThis study compares methotrexate alone versus methotrexate plus the antidepressant escitalopram in 40 adults with moderate to severe psoriasis and depression or anxiety. Over six months, researchers will measure skin improvement and mental health changes to see if the combination…
Phase: PHASE4 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a shot clear up acne? new mRNA vaccine trial begins
Disease control Recruiting nowThis study tests an experimental mRNA vaccine designed to treat moderate to severe acne in adults aged 18 to 45. The vaccine is given as up to three injections into the muscle. Researchers will monitor safety, immune response, and how well it reduces acne lesions. The trial invol…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug B007 aims to tame pemphigus with fewer meds
Disease control Recruiting nowThis study tests a new drug called B007 in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission while using minimal other treatments. Participants receive injections of B007 at high or low doses, and…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Laser light may replace steroids for chronic mouth pain
Disease control Recruiting nowThis study compares three treatments for painful mouth sores caused by oral lichen planus, a long-term inflammatory condition. Sixty adults will receive either a steroid cream (standard care) or one of two light-based therapies (photobiomodulation or photodynamic therapy) to see …
Phase: NA • Sponsor: Medical University of Silesia • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental CAR-T therapy takes on lupus and arthritis
Disease control Recruiting nowThis study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Cord stem cells aim to tame muscle disease and cut steroid use
Disease control Recruiting nowThis study tests whether stem cells from umbilical cord lining can safely reduce symptoms of dermatomyositis and polymyositis, two autoimmune diseases that cause muscle weakness and inflammation. About 40 adults will receive three doses of stem cells or a placebo, then switch. Re…
Phase: PHASE2, PHASE3 • Sponsor: Restem, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a shorter antibiotic course for lyme disease be just as effective?
Disease control Recruiting nowThis trial is testing whether a 7-day course of doxycycline works as well as the standard 14-day course for people with multiple erythema migrans, a sign of early Lyme disease. About 200 participants will be randomly assigned to one of the two treatment durations. Researchers wil…
Phase: NA • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New pill could tame tough psoriasis without injections
Disease control Recruiting nowThis Phase 3 trial tests D-2570, a new daily pill, in 477 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570, an active comparator (BMS-986165), or a placebo. The study measures how well the drug clears skin and improves quality …
Phase: PHASE3 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug picankibart aims to treat stubborn hand and foot pustules
Disease control Recruiting nowThis study tests a drug called picankibart in 60 adults with moderate-to-severe palmoplantar pustulosis, a painful skin condition causing pus-filled blisters on hands and feet. Participants receive injections of picankibart over nearly a year. The goal is to see if it reduces the…
Phase: NA • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody drug aims to halt skin and hair loss
Disease control Recruiting nowThis early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for stubborn eczema? abrocitinib tested after biologics fail
Disease control Recruiting nowThis study is tracking 150 adults and teens with moderate-to-severe eczema who have already tried up to two biologic drugs without success. Researchers want to see how well the oral medication abrocitinib (Cibinqo) works in real-world settings. The main goals are to measure impro…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on rare muscle disorders
Disease control Recruiting nowThis Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and red…
Phase: PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug ICP-332 aims to soothe stubborn hives when antihistamines fail
Disease control Recruiting nowThis study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a single infusion of supercharged immune cells tame incurable autoimmune diseases?
Disease control Recruiting nowThis early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …
Phase: NA • Sponsor: LiangZou • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a vitamin a drug or light boost nail fungus cure?
Disease control Recruiting nowThis study tests whether adding low dose isotretinoin (a vitamin A drug) or excimer light to standard itraconazole pills works better for nail fungus. 36 adults with onychomycosis will be split into three groups: itraconazole alone, itraconazole plus isotretinoin, or itraconazole…
Phase: PHASE1 • Sponsor: Zagazig University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Laser zaps away lichen sclerosus symptoms in new trial
Disease control Recruiting nowThis study tests a fractional 2940 nm laser to treat lichen sclerosus lesions in 50 women aged 18 and older. The laser aims to reduce symptoms like itching, burning, and painful intercourse by removing damaged tissue and promoting healing. Researchers will check tissue samples 16…
Phase: NA • Sponsor: Sciton • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can kids with eczema take less medicine? new study aims to find out
Disease control Recruiting nowThis study looks at whether children aged 1 to 17 with well-controlled atopic dermatitis (eczema) can safely reduce their dose or stop taking dupilumab (Dupixent) without their skin condition getting worse. About 30 children who have been on dupilumab for at least a year and have…
Phase: PHASE4 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill could stop scalp scarring and hair loss
Disease control Recruiting nowThis study tests an oral medication called brepocitinib for adults with lichen planopilaris, a condition that causes scalp inflammation, scarring, and hair loss. About 342 participants will receive either the drug or a placebo to see if it reduces symptoms and improves scalp appe…
Phase: PHASE2, PHASE3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New study explores best guselkumab dose for psoriasis in chinese patients
Disease control Recruiting nowThis study compares the effectiveness and safety of different doses and schedules of guselkumab in 400 Chinese adults with moderate to severe plaque psoriasis. Participants will receive either a high dose, an extended-interval dose, or the standard dose. The goal is to find the b…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill for chronic hives tested in thousands of patients
Disease control Recruiting nowThis study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for chronic hives? experimental drug lesigercept enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…
Phase: PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot for eczema shows promise in early trial
Disease control Recruiting nowThis study tests an experimental drug called SHR-1905 in 75 adults with moderate-to-severe atopic dermatitis (eczema). Half will get the drug, half a placebo, and neither they nor their doctors will know who got what. The main goal is to see if the drug can reduce eczema severity…
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New shot could tame stubborn hives that antihistamines Can't
Disease control Recruiting nowThis Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibody treatment offers hope for rare blistering skin disease
Disease control Recruiting nowThis study tests a new drug called CM336 in 30 adults with moderate to severe autoimmune bullous disease, a condition where the immune system attacks the skin causing painful blisters. The drug targets specific immune cells to reduce this attack. The main goal is to see if the dr…
Phase: PHASE2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Good bacteria cream could be new acne weapon
Disease control Recruiting nowThis study tests a cream made from a common probiotic, Lactobacillus reuteri, that has been coated with a special material to help it survive on the skin. The goal is to see if it can rebalance the skin's bacteria and reduce acne. About 196 people with mild to moderate acne will …
Phase: PHASE2 • Sponsor: Shenzhen People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New liquid drug offers hope for kids with severe eczema
Disease control Recruiting nowThis 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New pill vs. injection: which works better for kids with severe eczema?
Disease control Recruiting nowThis study tests two medicines for children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. One group gets upadacitinib (a daily pill or liquid), the other gets dupilumab (an injection every 2 or 4 weeks). The goal is to see which better reduces skin …
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New shot could tame severe eczema in teens
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called SHR-1819 in about 200 teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo injection. The study measures how well the drug clears skin rashes and reduces …
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for painful hand and foot skin disease: experimental drug enters trial
Disease control Recruiting nowThis study tests a new biologic drug called Xeligekimab in 10 adults with moderate to severe palmoplantar pustulosis (PPP), a chronic skin disease causing painful blisters and scales on the palms and soles. The goal is to see if the drug can reduce symptoms and improve quality of…
Phase: PHASE4 • Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New injection aims to stop dangerous psoriasis flares in their tracks
Disease control Recruiting nowThis phase 2 trial tests an injection called TQH2929, a lab-made antibody that blocks inflammation, in 36 adults having a sudden, severe flare of generalized pustular psoriasis (GPP). Half get the drug, half get a placebo. The main goal is to see if the drug clears pustules withi…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New skin disease drug enters first human trials
Disease control Recruiting nowThis study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Real-World study tests nemolizumab for persistent eczema itch
Disease control Recruiting nowThis study is tracking 1,000 adolescents and adults with moderate-to-severe atopic dermatitis (eczema) who are starting treatment with nemolizumab (Nemluvio®) in real-world clinics. The main goal is to see how well the drug controls skin symptoms and itching after 6 months, using…
Sponsor: Galderma R&D • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a magnolia supplement calm psoriasis inflammation?
Disease control Recruiting nowThis study tests whether a daily magnolia bark supplement (Viv) can reduce immune-related blood markers in adults with psoriasis. One hundred participants will take either the supplement or a placebo for three months. Researchers will measure changes in inflammatory proteins and …
Phase: NA • Sponsor: Sirt3 LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New shot for eczema shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called IBI356 in about 400 adults with moderate to severe atopic dermatitis (eczema). Participants receive either IBI356, dupilumab (an existing treatment), or a placebo by injection. The main goal is to see if IBI356 reduces eczema severity and itchin…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cosentyx under Real-World watch for kids and adults with skin and joint disease
Disease control Recruiting nowThis study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Turmeric power: could curcumin nanogels replace steroids for a painful mouth condition?
Disease control Recruiting nowThis study compares curcumin nanogels (a natural turmeric extract) to a standard steroid paste for treating atrophic-erosive oral lichen planus, a chronic inflammatory mouth condition. Thirty adults will apply either treatment three times daily for four weeks. Researchers will me…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may end guesswork in psoriasis dosing
Disease control Recruiting nowThis study tests whether measuring biologic drug levels in the blood can help doctors adjust doses for people with psoriasis. About 210 adults on certain biologics will either get dose advice based on blood tests or continue standard care. The goal is to maintain disease control …
Phase: PHASE4 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for genital eczema: drug trial targets severe itch and pain
Disease control Recruiting nowThis study tests whether tralokinumab, an approved eczema drug, can improve moderate-to-severe atopic dermatitis in the genital area. About 30 adults will receive the drug and be monitored for 52 weeks using special skin imaging and symptom questionnaires. The goal is to see if i…
Sponsor: University Hospital Schleswig-Holstein • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
One shot before transplant could save kidneys
Disease control Recruiting nowThis study tests whether a single injection of Berinert, a protein that reduces inflammation, into a donor kidney just before transplant can improve kidney function in the first year. Researchers will compare this to a placebo in 180 high-risk patients receiving deceased-donor ki…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a hormone drug help restore skin color in vitiligo?
Disease control Recruiting nowThis Phase 2 study tests whether adding Melanotan II (a synthetic hormone-like drug) to standard narrowband UV-B light therapy helps restore skin color in adults with stable nonsegmental vitiligo. About 60 participants will receive either the drug or a placebo, plus light therapy…
Phase: PHASE2 • Sponsor: Hudson Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New eye drop takes on pesky eyelash mites
Disease control Recruiting nowThis study tests an experimental eye drop called GLK-321 in 250 adults with Demodex blepharitis, a condition where tiny mites cause debris at the base of eyelashes. Participants will receive either a low, mid, or high dose of the drug, or a placebo, for 6 weeks. The main goal is …
Phase: PHASE2 • Sponsor: Glaukos Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Plant-Based cream shows promise for psoriasis in new trial
Disease control Recruiting nowThis phase 3 trial tests a cream made from plant compounds (total coumarins) for treating psoriasis vulgaris. 300 adults will apply the cream or a placebo twice daily for 8 weeks. Researchers will check if the cream improves skin symptoms and quality of life, and monitor for side…
Phase: PHASE3 • Sponsor: Psoriasis Research Institute of Guangzhou • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Psoriasis patients may get longer breaks between injections
Disease control Recruiting nowThis study looks at whether people with psoriasis who are doing very well on the drug guselkumab (Tremfya) can safely wait longer than the usual 8 weeks between injections. Researchers will track 100 adults whose doctors have already extended their dosing intervals to see how the…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Biosimilar switch for asthma and hives under Real-World study
Disease control Recruiting nowThis study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 1…
Sponsor: Celltrion HealthCare France • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a contraceptive gel ward off vaginal infections?
Disease control Recruiting nowThis early study tests whether a lactic acid gel (Phexxi) used twice weekly can change the vaginal microbiome to help prevent recurrent bacterial vaginosis and yeast infections. 22 premenopausal women with a history of these infections will use the gel for 4 weeks. Researchers wi…
Phase: EARLY_PHASE1 • Sponsor: Queen's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Smart antibody monitoring could prevent pemphigus Flare-Ups
Disease control Recruiting nowThis study tests a personalized approach to treating pemphigus, a rare blistering skin disease. Instead of waiting for a relapse, doctors will use blood tests to measure specific antibodies and give extra rituximab infusions only when those levels rise. The goal is to prevent fla…
Phase: PHASE4 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Honey vs. steroids: can a sweet paste soothe chronic mouth pain?
Disease control Recruiting nowThis study tests a honey-based paste against a standard steroid ointment for treating painful mouth sores caused by oral lichen planus. Fifty-six adults with erosive or atrophic lichen planus will use the paste daily for four months. Researchers will track symptom improvement, pa…
Phase: PHASE2, PHASE3 • Sponsor: Dar Al Uloom University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill could tame stubborn hives that antihistamines Can't stop
Disease control Recruiting nowThis study tests an experimental drug called BLU-808 for people with chronic hives (urticaria) that don't get better with standard antihistamines. The drug works by blocking a protein called KIT, which may help control the allergic reaction causing the hives. About 105 adults wil…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a pill and gel combo restore skin color in vitiligo?
Disease control Recruiting nowThis study tests a new drug called SHR0302, given as a tablet and a gel, for people with non-segmental vitiligo. The goal is to see if it can safely and effectively bring back skin color. About 176 adults aged 18 to 75 will take part, and some will receive a placebo to compare re…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can microneedling with a chemo drug restore skin color in vitiligo?
Disease control Recruiting nowThis early-stage trial compares two treatments for limited vitiligo: microneedling with 5-fluorouracil (5FU) every two weeks versus a strong steroid cream applied twice daily. Forty participants aged 5 to 70 with vitiligo on 10% or less of their body will be treated for 12 weeks.…
Phase: EARLY_PHASE1 • Sponsor: Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a diabetes pill also calm psoriasis? new study aims to find out
Disease control Recruiting nowThis study tests whether adding semaglutide (a drug used for diabetes and weight loss) to a standard topical cream can improve psoriasis symptoms and reduce body-wide inflammation. About 62 adults with plaque psoriasis who are overweight or have type 2 diabetes will receive eithe…
Phase: PHASE4 • Sponsor: Hospital Universitario Dr. Jose E. Gonzalez • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Ancient needles and herbs take on psoriasis in new trial
Disease control Recruiting nowThis study compares two treatments for mild-to-moderate plaque psoriasis: acupuncture combined with a Chinese herbal cream versus acupuncture combined with a standard medicated cream (calcipotriol). About 28 adults with psoriasis on skin, scalp, or nails will be enrolled. Researc…
Phase: PHASE2 • Sponsor: Mae Fah Luang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug for chronic hives tested in everyday practice
Disease control Recruiting nowThis study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal i…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill could clear psoriasis skin in major trial
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called ICP-488 in 383 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can significantly clear or nearly clear the sk…
Phase: PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug may stop scalp scarring and hair loss
Disease control Recruiting nowThis pilot study tests nemolizumab, a drug already approved for other skin conditions, in 10 adults with lichen planopilaris (LPP), a disease that causes permanent hair loss and scalp itching or burning. The goal is to see if the drug can reduce disease activity and improve sympt…
Phase: PHASE4 • Sponsor: The Skin Center Dermatology Group • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug trial targets skin and scalp woes in down syndrome
Disease control Recruiting nowThis study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure …
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill could soothe severe eczema – trial underway
Disease control Recruiting nowThis study tests whether ZL-82 tablets can safely reduce eczema symptoms in adults with moderate to severe atopic dermatitis. About 111 participants will take either the drug or a placebo daily for 16 weeks, with regular checkups. The main goal is to see if ZL-82 improves skin se…
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cooling device may soothe yeast infections without drugs
Disease control Recruiting nowThis study is testing a new cooling device placed in the vagina to treat yeast infections. Researchers want to see if it can relieve symptoms and clear the infection within 7 days. The study involves 55 women aged 22-49 with uncomplicated yeast infections. It is an early-stage tr…
Phase: NA • Sponsor: Coologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early access program opens for upadacitinib in Crohn's, colitis, arthritis, and eczema
Disease control AVAILABLEThis program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential ben…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a drug calm this rare muscle and lung disease?
Disease control Recruiting nowThis study tests whether tocilizumab, a drug that blocks inflammation, can improve symptoms and breathing in adults with anti-MDA5+ dermatomyositis, a rare autoimmune disease affecting muscles, skin, and lungs. About 110 participants will receive either tocilizumab or a placebo e…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a daily patch fix your toenails? new trial aims to find out
Disease control Recruiting nowThis study tests a special hydrogel patch applied daily to toenails for three months. It is designed for people with nail fragility, fungal infections, or nail psoriasis. The trial includes 72 adults and compares the active patch to a placebo to see if it safely improves nail hea…
Phase: PHASE3 • Sponsor: Wooshin Labottach Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New combo treatment tested for painful skin condition
Disease control Recruiting nowThis study tests whether adding a special radiofrequency treatment to standard steroid cream works better than steroid cream alone for women with vulvar lichen sclerosus, a chronic skin condition causing itching, pain, and discomfort. About 68 women of reproductive age will be ra…
Phase: NA • Sponsor: Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New biosimilar aims to offer cheaper eczema treatment
Disease control Recruiting nowThis early-stage trial tests a new drug called CKD-706, which is a biosimilar (a close copy) of the approved eczema treatment Dupixent. The study involves 519 healthy adults who will receive a single injection of either CKD-706, the US version of Dupixent, or the European version…
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Which drug tames skin vasculitis best? new trial aims to find out
Disease control Recruiting nowThis study tests three standard medications—colchicine, dapsone, and azathioprine—in 90 people with isolated skin vasculitis (inflammation of small or medium blood vessels in the skin). Participants are randomly assigned to one of the drugs, and doctors track how well the skin re…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could a common arthritis drug ease a devastating skin condition?
Disease control Recruiting nowThis study tests whether methotrexate, a drug used for arthritis, can help women with severe vulvar lichen sclerosus that hasn't improved with standard steroid creams. Twelve women will receive weekly injections of methotrexate for 12 months. The goal is to see if symptoms and sk…
Phase: PHASE2 • Sponsor: Clinica Dermatologica Arbache ltda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New gel aims to recolor white patches on face
Disease control Recruiting nowThis early-stage trial tests whether CGB-600 gel can safely reduce white patches from vitiligo on the face and neck. Thirty-six adults will apply the gel or a placebo twice daily for 24 weeks. Researchers will check for side effects and measure if the patches shrink by at least 5…
Phase: PHASE1 • Sponsor: CAGE Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Which pill works best for tough ringworm? new study aims to find out
Disease control Recruiting nowThis study compares two common oral antifungal pills—fluconazole and itraconazole—in adults with ringworm that hasn't cleared up with creams. 126 people aged 18-70 with persistent infection for at least 6 months will be randomly assigned to one of the two drugs for 4 weeks. The g…
Phase: PHASE4 • Sponsor: Urooj Fatima • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Psoriasis drug showdown: which works better?
Disease control Recruiting nowThis study compares two drugs, methotrexate and apremilast, to see which works better for moderate to severe plaque psoriasis. About 106 adults with psoriasis will take one of the drugs for 12 weeks. The goal is to find which treatment reduces skin symptoms more effectively.
Phase: EARLY_PHASE1 • Sponsor: Syeda Sana Zaman • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill could tame blistering skin disease without high steroid doses
Disease control Recruiting nowThis phase 3 study tests an experimental drug called tirabrutinib for people with pemphigus, a rare autoimmune disease that causes painful blisters on skin and mucous membranes. The trial enrolls 34 adults whose disease is not well controlled by steroids. Participants receive eit…
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Fizzing powder may restore skin color in vitiligo
Disease control Recruiting nowThis study tests a new effervescent (fizzing) powder containing 5-fluorouracil to treat vitiligo, a condition that causes white patches on the skin. Sixty people with stable vitiligo will apply either the new fizzing powder or plain 5-fluorouracil powder to their patches. The goa…
Phase: PHASE4 • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could cold plasma zap away stubborn Athlete's foot?
Disease control Recruiting nowThis study tests a new device that uses cold plasma (a type of energized gas) to treat moderate-to-severe athlete's foot, a stubborn fungal infection. About 220 adults with confirmed infection will receive either the plasma treatment or a fake one to see if it safely reduces skin…
Phase: NA • Sponsor: Shenyang Medical College • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill aims to recolor white patches in vitiligo patients
Disease control Recruiting nowThis study tests a new drug called VC005 in 120 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants will take either VC005 or a placebo daily for 52 weeks. The main goal is to see if the drug can reduce the size of white patches on …
Phase: PHASE2 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New study seeks to unlock secrets of vitiligo Cream's success
Disease control Recruiting nowThis study is testing a cream called ruxolitinib on 170 people with vitiligo, a skin condition that causes white patches. The goal is to find out what factors help the cream work best. Participants must be 12 or older and have mild to moderate vitiligo. They will stop other treat…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could cold plasma be the next acne breakthrough?
Disease control Recruiting nowThis study tests whether cold atmospheric plasma (CAP) can safely and effectively treat moderate-to-severe acne. 220 adults aged 18-40 will receive either CAP or a placebo treatment once a week for six weeks. The goal is to see if CAP reduces acne lesions better than placebo, off…
Phase: NA • Sponsor: Shenyang Medical College • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a measles vaccine cure stubborn ringworm?
Disease control Recruiting nowThis pilot study is testing whether injecting the MMR vaccine directly into skin lesions can help treat hard-to-clear fungal infections (tinea cruris and corporis). The study will enroll 50 people aged 10-60 who have not improved with standard antifungal treatments. Participants …
Phase: NA • Sponsor: Abeer Mohamed Abdelaziz Elkholy • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could an asthma pill tame tough eczema?
Disease control Recruiting nowThis pilot study is testing whether an oral medication called roflumilast (already used for other conditions) can help people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). 36 participants will take a daily pill for 12 weeks. The study measures changes in e…
Phase: PHASE2 • Sponsor: Nora Mohamed Abdelrazik • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill could ease severe psoriasis in just 12 weeks
Disease control Recruiting nowThis phase 2 trial tests an experimental oral drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. Participants take the drug or placebo daily for 12 weeks. The main goal is to see if at least 75% of skin symptoms improve. If it works, ICP…
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could 'Good' bacteria on your skin tame psoriasis? new trial aims to find out
Disease control Recruiting nowThis study tests whether applying a solution of Lactobacillus plantarum, a beneficial bacteria from healthy skin, to psoriasis patches can improve the condition. 184 adults with mild-to-moderate psoriasis will apply the bacteria or an inactive version daily for two months. The go…
Phase: PHASE2 • Sponsor: Shenzhen People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New shot could clear teen psoriasis – trial underway
Disease control Recruiting nowThis study tests a drug called picankibart in teenagers aged 12 to 18 with moderate-to-severe plaque psoriasis. Half get the drug, half get a placebo, and researchers check if their skin clears up after 16 weeks. The goal is to see if it's safe and works better than a dummy treat…
Phase: PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Promising cream may help kids with vitiligo regain skin color
Disease control Recruiting nowThis study tests a cream called ruxolitinib in 180 children with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. Participants will apply the cream daily for several mont…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New eczema drug ZL-1503 enters first human safety trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…
Phase: PHASE1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Cheaper psoriasis drug on the horizon? new biosimilar enters human trials
Disease control Recruiting nowThis Phase 1 trial tests a new biosimilar called CKD-704, which is designed to be a more affordable copy of the psoriasis drug Skyrizi (risankizumab). The study involves 213 healthy adults who will receive a single dose of either CKD-704, the EU-approved Skyrizi, or the US-licens…
Phase: PHASE1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cream could help kids with vitiligo regain skin color
Disease control Recruiting nowThis study tests a cream called ruxolitinib in children aged 6 to 12 with nonsegmental vitiligo, a condition that causes white patches on the skin. The cream is applied twice daily to affected areas. The goal is to see if it can safely restore skin color. About 250 children will …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New psoriasis pill shows promise in major trial
Disease control Recruiting nowThis study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if the drug can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for at lea…
Phase: PHASE3 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New eczema drug cibinqo under Real-World safety review in korea
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the prescription drug Cibinqo (abrocitinib) in people with moderate to severe atopic dermatitis (a type of eczema). About 1,100 participants in Korea will take the tablet as prescribed by their doctor and be observed for on…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New daily pill shows promise for controlling stubborn eczema in real life
Disease control Recruiting nowThis study is tracking 183 adults with moderate-to-severe atopic dermatitis (eczema) who are taking abrocitinib, a daily tablet. Researchers want to see how well the drug works in real-life settings, not just in controlled clinical trials. Participants will be followed for 24 mon…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill hopes to clear stubborn hand and foot blisters
Disease control Recruiting nowThis study tests a daily pill called ivarmacitinib for palmoplantar pustulosis (PPP), a chronic skin condition causing painful blisters on hands and feet. Sixty adults who haven't improved with other treatments will take the pill for 12 weeks. Researchers will check if symptoms l…
Phase: NA • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Ultrasound boosts steroid cream for vitiligo in new trial
Disease control Recruiting nowThis study tests if using ultrasound (phonophoresis) to push betamethasone cream deeper into the skin can help control vitiligo, a condition that causes white patches. Researchers will enroll 60 adults with vitiligo who are otherwise healthy. The goal is to see if this approach r…
Phase: NA • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug hope for stubborn hives patients
Disease control AVAILABLEThis program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access t…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Psoriasis drug showdown: which pill works best?
Disease control Recruiting nowThis study compares two oral medications, methotrexate and tofacitinib, to see which is more effective at reducing psoriasis plaques. It involves 75 adults with moderate to severe chronic plaque psoriasis who have not responded well to topical treatments. The main goal is to meas…
Phase: EARLY_PHASE1 • Sponsor: Lahore General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill for psoriasis tested in everyday clinics
Disease control Recruiting nowThis study follows 200 Italian patients with moderate-to-severe psoriasis who are already taking deucravacitinib, a daily pill that calms the immune system. Researchers will track how well the drug controls skin symptoms, its side effects, and how it affects quality of life in re…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Laser may offer new hope for women with chronic vulvar condition
Disease control Recruiting nowThis study tests whether a fractional CO2 laser can reduce inflammation and symptoms like itching and pain in vulvar lichen sclerosus, a chronic skin condition. Forty women who have not been treated before will receive either standard clobetasol ointment or three laser sessions. …
Phase: NA • Sponsor: Universidade Federal do Rio de Janeiro • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy could ease painful mouth condition
Disease control Recruiting nowThis study tests whether adding the drug tofacitinib to standard steroid ointment can better control oral lichen planus, a chronic inflammatory mouth condition. About 60 adults with moderate to severe disease will receive either tofacitinib pills or placebo alongside their usual …
Phase: PHASE4 • Sponsor: All India Institute of Medical Sciences, Bhubaneswar • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New antifungal stick could simplify Athlete's foot treatment
Disease control Recruiting nowThis Phase 2 trial tests three different stick formulations of the antifungal drug tolnaftate (1%) for treating athlete's foot (tinea pedis). About 150 people aged 16 and older with a confirmed diagnosis will apply the stick twice daily for 4 weeks. The main goal is to see if the…
Phase: PHASE2 • Sponsor: Propedix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New study tests if early drug use can stop psoriasis from becoming chronic
Disease control Recruiting nowThis study tests whether early use of the drug bimekizumab can delay or prevent chronic inflammation in people with mild plaque psoriasis. 40 adults with recent-onset or long-standing mild psoriasis will receive either bimekizumab injections or a topical steroid cream. The goal i…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug aims to restore skin color in vitiligo patients
Disease control Recruiting nowThis early-stage trial tests a new drug called FB102 in 64 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Half will get the drug and half a placebo, both given by IV. The main goal is to check safety and see if the drug helps bring back ski…
Phase: PHASE1 • Sponsor: Forte Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Massive drug showdown: can a new pill beat river blindness for good?
Disease control Recruiting nowThis study compares two drugs, ivermectin and moxidectin, to see which works better at controlling river blindness and other common infections like intestinal worms and scabies in Angola. Over 52,000 people in 20 village groups will receive one of the drugs once a year for four y…
Phase: PHASE4 • Sponsor: Kirby Institute • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New eczema drug CM512 tested for Long-Term safety in 246 patients
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who have already finished a previous CM512 study. The main goal is to track any side effects over time.
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could a leaf cream beat 'Shifting Clouds' skin spots?
Disease control Recruiting nowThis early study tests a cream made from cassia alata, a plant, on 20 adults with tinea versicolor (light or dark patches on skin). Participants apply the cream to one area and leave another area untreated for comparison. Researchers check if the treated skin clears up better and…
Phase: PHASE1 • Sponsor: The University of The West Indies • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New shot could clear eczema in teens – trial underway
Disease control Recruiting nowThis Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main go…
Phase: PHASE3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New gel aims to stop recurring vaginal infections
Disease control Recruiting nowThis study tests a gel device called Multi-Gyn FemiTotal in 80 women with bacterial vaginosis or vaginal yeast infections. Participants use the gel for 7 days, and if symptoms clear, they are followed for 4 months to see if the infection returns. The goal is to see if the gel can…
Phase: NA • Sponsor: Karo Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill could clear psoriasis in weeks
Disease control Recruiting nowThis study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.
Phase: NA • Sponsor: Usynova Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New screening tool aims to catch hidden arthritis in psoriasis patients
Diagnosis Recruiting nowThis Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…
Phase: NA • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New PET tracer aims to reveal hidden inflammation in cancer patients
Diagnosis Recruiting nowThis early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Could a single blood test speed up HAE diagnosis?
Diagnosis Recruiting nowThis study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part.…
Phase: NA • Sponsor: Takeda • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New imaging tool could make mouth biopsies more accurate
Diagnosis Recruiting nowThis study tests a new imaging device called the Active Biopsy Guidance System to help doctors decide when and where to take tissue samples (biopsies) from mouth lesions. About 90 adults with suspicious mouth spots or a history of oral cancer will participate. The goal is to see …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
New handheld scanner could replace MRI for muscle disease monitoring
Diagnosis Recruiting nowThis study is testing a handheld device called mScan that uses a tiny, painless electrical current to measure muscle health. Researchers want to see if it can give similar results to an MRI, but faster and more conveniently. The study involves 150 adults with and without muscle d…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
Doctor's eye vs. paper quiz: which finds hidden arthritis in psoriasis patients?
Diagnosis Recruiting nowThis study tests whether a dermatologist's physical exam is better than a patient questionnaire at spotting psoriatic arthritis (PsA) in people with psoriasis. About 500 adults with psoriasis will be checked by both methods, then referred to a rheumatologist for a final diagnosis…
Sponsor: Charite University, Berlin, Germany • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
AI reads your skin: new tool aims to help doctors spot rashes and moles
Diagnosis Recruiting nowThis study is testing a software tool called Belle.ai that uses artificial intelligence to help doctors diagnose common skin diseases. About 400 patients at dermatology clinics will have three photos taken of their skin condition. The AI will analyze the photos and suggest possib…
Sponsor: Wake Forest University Health Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Can a common antiseptic spray stop radiation burns in cancer patients?
Prevention Recruiting nowThis study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …
Phase: PHASE3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
Could a simple cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis study tests a cream called Pinoxin to see if it can prevent skin injuries caused by radiation therapy in cancer patients. About 202 adults receiving high-dose radiation will be randomly assigned to use either Pinoxin or a placebo cream. The main goal is to see if Pinoxin low…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
New cream may stop radiation burns in cancer patients
Prevention Recruiting nowThis study tests a new cream made from amino acids to prevent skin damage caused by radiation therapy in people with head and neck cancer. About 40 participants will use the cream during their radiation treatment. The goal is to see if it reduces skin redness, pain, and treatment…
Phase: NA • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Common pain gel could shield cancer patients from radiation burns
Prevention Recruiting nowThis study tests whether a gel containing diclofenac, a common anti-inflammatory drug, can prevent severe skin irritation caused by radiation therapy. About 156 adults with head/neck or breast cancer will apply the gel or a placebo to the treated skin three times daily during the…
Phase: NA • Sponsor: The Second Affiliated Hospital of Hainan Medical University • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Breakthrough trial aims to prevent arthritis in psoriasis patients
Prevention Recruiting nowThis study tests whether the drug guselkumab can prevent psoriatic arthritis in people with psoriasis who are at high risk. 176 adults with psoriasis and early signs of joint inflammation will receive either guselkumab or standard care. The goal is to see if the drug can stop art…
Phase: PHASE4 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Cockroach extract may shield cancer patients from radiation burns
Prevention Recruiting nowThis study tests a liquid made from cockroach extract (Meilian Fuxin) to prevent severe skin damage in head and neck cancer patients receiving radiation therapy. About 60 participants will apply the solution to their skin during treatment. The goal is to see if it reduces the ris…
Phase: PHASE2, PHASE3 • Sponsor: West China Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Good bacteria for gassy babies: new study tests probiotic to stop colic before it starts
Prevention Recruiting nowThis study is testing whether giving healthy newborns a probiotic supplement (L. reuteri) can prevent colic and excessive crying. About 768 babies will receive either the probiotic or a placebo daily for the first 3 months. Researchers will track crying, fussiness, and stool patt…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
New hydrogel aims to stop radiation burns in breast cancer patients
Prevention Recruiting nowThis study tests a hydrogel made from bacterial cellulose and coconut oil monolaurin to prevent severe skin reactions in Filipino women with breast cancer undergoing radiation therapy. About 54 participants will apply either the hydrogel or a placebo cream daily. The goal is to s…
Phase: NA • Sponsor: University of the Philippines • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Baby formula breakthrough? new study tests synbiotics to stop eczema before it starts
Prevention Recruiting nowThis study tests whether a partially hydrolyzed formula with added synbiotics can prevent atopic dermatitis (eczema) in 400 infants at high risk for allergies. Babies are enrolled within 14 days of birth and followed for skin barrier function and eczema development. The goal is t…
Phase: NA • Sponsor: Société des Produits Nestlé (SPN) • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Could a common supplement shield breast cancer patients from radiation burns?
Prevention Recruiting nowThis study tests whether taking alpha lipoic acid, a common antioxidant supplement, can prevent or reduce skin irritation caused by radiation therapy in breast cancer patients. Researchers will enroll 40 women with early-stage breast cancer who are scheduled for radiation. The go…
Phase: NA • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Can a smartphone app ease the misery of eczema, psoriasis, and hives?
Symptom relief Recruiting nowThis study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 198 participants will receive either BBT001 or a placebo, wit…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Could a flower extract help heal irritated skin faster?
Symptom relief Recruiting nowThis study tests whether a cream made with Helichrysum italicum (Immortelle) extract can help heal irritated skin and restore the skin barrier better than a plain moisturizer. Healthy volunteers will have a small patch of skin irritated with a mild soap, then apply the Immortelle…
Phase: NA • Sponsor: University of Split, School of Medicine • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a natural fiber cream soothe painful incontinence rashes?
Symptom relief Recruiting nowThis study tests whether adding a beta-glucan moisturizing cream to standard skin care helps heal incontinence-associated dermatitis faster and reduces symptoms like pain, itching, and burning. Sixty adults with this skin condition will receive either the cream plus standard care…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New eczema ointment shows promise in early trial
Symptom relief Recruiting nowThis study tests an ointment called HL-300 in people with mild-to-moderate atopic dermatitis (eczema). About 156 adults will apply the ointment or a placebo twice daily for 4 weeks. Researchers will check if the ointment reduces eczema severity and improves symptoms.
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New pill could soothe stubborn hives when allergy meds fail
Symptom relief Recruiting nowThis study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New lotion shows promise for flaky scalp and skin
Symptom relief Recruiting nowThis study tests a new lotion (ZYG24002) in 48 adults with mild to moderate seborrheic dermatitis, a common skin condition causing redness and flaking. Participants will apply the lotion daily for 28 days to see if it is safe and tolerable. The goal is to find the best dose for f…
Phase: PHASE1 • Sponsor: Sinomune Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New serum could soothe flaky facial skin
Symptom relief Recruiting nowThis study tests whether a special antioxidant moisturizing serum can improve mild to moderate seborrheic dermatitis on the face. Researchers will apply the serum to one side of the face and a control product to the other side for 4 weeks in 13 adults. The goal is to see if the s…
Phase: NA • Sponsor: Institute of Dermatology, Thailand • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Pineapple enzyme takes on steroids in mouth sore battle
Symptom relief Recruiting nowThis study compares a pineapple-derived enzyme (bromelain) to standard steroid treatment for oral lichen planus, a chronic inflammatory condition causing painful mouth sores. Researchers will enroll 42 adults with symptoms to see if bromelain reduces sores and pain as effectively…
Phase: PHASE2 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Could a Cardamom-Bacteria spray soothe your eczema?
Symptom relief Recruiting nowThis study tests if a spray made from ground cardamom seeds and a harmless skin bacteria (Roseomonas mucosa) can improve eczema symptoms in people aged 2 and older. Participants apply the spray 2-3 times a week for 14 weeks and are monitored remotely for about 7 months. Half rece…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New acne pill enters first human tests
Symptom relief Recruiting nowThis early-stage trial tests an experimental oral drug called TVB-3567 in 128 healthy adults, some with acne. The main goal is to check safety and how the body processes the drug, not yet whether it works. Results will help decide if larger studies are warranted.
Phase: PHASE1 • Sponsor: Sagimet Biosciences Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New cream could soothe eczema in babies as young as 3 months
Symptom relief Recruiting nowThis study tests a cream called tapinarof on babies and toddlers aged 3 to 23 months with eczema (atopic dermatitis). The goal is to see if it can clear or nearly clear their skin rash. About 180 children will take part, and the cream is compared to a placebo (inactive cream) for…
Phase: PHASE3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New eczema pill shows promise in early trial
Symptom relief Recruiting nowThis study tests whether a new oral drug called ENV-294 can safely reduce eczema severity in adults with moderate-to-severe atopic dermatitis. Sixty participants will take either ENV-294 or a placebo pill daily for 12 weeks. Researchers will measure changes in skin symptoms and t…
Phase: PHASE2 • Sponsor: Enveda Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for stubborn hives in Head-to-Head trial
Symptom relief Recruiting nowThis study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Could a higher dose of allergy medicine beat hives faster?
Symptom relief Recruiting nowThis study compares the standard dose of cetirizine (10 mg daily) to a higher dose (40 mg daily) for treating acute hives in adults. Researchers want to see if the higher dose relieves symptoms faster and reduces the need for steroid rescue medication. Participants take the assig…
Phase: NA • Sponsor: University of Phayao • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New oral spray aims to ease sore throat and canker sores without drugs
Symptom relief Recruiting nowThis study is testing an oral spray called OROSEDAL to see if it helps relieve pain from sore throats, canker sores, and other minor mouth lesions. About 124 children and adults will use the spray as prescribed and report their pain levels over 6 days. The spray works by forming …
Sponsor: Laboratoires Elerte • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Mindfulness may soothe psoriasis stress
Symptom relief Recruiting nowThis study tests whether Mindfulness-Based Cognitive Therapy (MBCT) can reduce psychological distress and improve self-compassion in people with psoriasis. Researchers will enroll 128 adults with psoriasis who are experiencing emotional difficulties. Participants will either rece…
Phase: NA • Sponsor: Islamia University of Bahawalpur • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New pill could ease severe eczema itch and rash
Symptom relief Recruiting nowThis study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Light therapy may soothe radiation burns in breast cancer patients
Symptom relief Recruiting nowThis study tests whether a special light therapy can reduce skin damage caused by radiation treatment in women with breast cancer. 60 women who have had breast-conserving surgery and are scheduled for radiation will either receive standard skin care alone or standard care plus po…
Phase: NA • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…
Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Could a probiotic boost yeast infection treatment?
Symptom relief Recruiting nowThis study tests whether adding a probiotic supplement (Bioithas WOMAN®) to standard antifungal medicine helps relieve symptoms of vaginal yeast infections faster. About 60 women with suspected yeast infections will take either antifungal treatment alone or with the probiotic for…
Phase: NA • Sponsor: Bioithas SL • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Vitamin c shots may replace the knife for dark gums
Symptom relief Recruiting nowThis study tests if injecting vitamin C and glutathione into dark gums can lighten them as well as surgery. About 30 adults with gum pigmentation will be randomly assigned to either injection or scalpel removal. The main goal is to see how much the color improves, and the study a…
Phase: PHASE2 • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New eye drop battle: which offers better dry eye relief?
Symptom relief Recruiting nowThis study compares two preservative-free eye drops, Artelac Complete MDO and VISMED MULTI, for treating moderate to severe dry eye disease. About 160 adults who have used tear substitutes for at least a month will use one of the two drops for 90 days. Researchers will measure ch…
Phase: NA • Sponsor: Dr. Gerhard Mann chem.-pharm. Fabrik GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New eczema ointment shows promise in early trial
Symptom relief Recruiting nowThis Phase 2 study tests an experimental ointment called GX-03 in adults with moderate-to-severe eczema. About 110 to 200 participants will apply either the active ointment or a placebo for 8 weeks. Researchers will measure improvements in skin rash, itch, and patient-reported sy…
Phase: PHASE2 • Sponsor: Turn Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Eczema drug dupilumab may lift anxiety and depression
Symptom relief Recruiting nowThis study tracks 184 people with moderate-to-severe atopic dermatitis (eczema) who are already starting dupilumab treatment. Over six months, researchers will measure changes in anxiety, depression, and quality of life using standard questionnaires. The goal is to see if treatin…
Sponsor: Sanofi • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can probiotic drops soothe baby tummies and skin?
Symptom relief Recruiting nowThis study tests whether a daily probiotic supplement called BioAmicus Complete can help infants with colic, constipation, diarrhea, and eczema. 140 babies will receive either the probiotic drops or a placebo (sunflower oil) for 25 days. Researchers will track changes in stool, c…
Phase: NA • Sponsor: NovoNatum Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Silk bandage vs. skin glue: which is gentler after ACL surgery?
Symptom relief Recruiting nowThis study tests whether a special silk dressing (SYLKE®) causes fewer skin problems like rashes, blisters, or redness compared to standard skin glue (Dermabond®) after ACL knee surgery. About 100 people aged 14 to 60 having ACL reconstruction will be randomly assigned to one of …
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goals are to check safety and how the body processes the drug. A small group of eczema patients will also be monitored for skin …
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Probiotic drink may soothe menopause skin woes
Symptom relief Recruiting nowThis study tests whether a daily probiotic drink can improve immune function and reduce skin inflammation in women aged 40-60 going through menopause. Participants will drink either a probiotic or a plain milk drink for 8 weeks. Researchers will measure immune aging, inflammation…
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Could a simple injection melt away painful calcium deposits?
Symptom relief Recruiting nowThis study tests whether injecting sodium thiosulfate directly into painful calcium deposits (calcinosis) can shrink them and ease symptoms. Twenty adults with scleroderma, dermatomyositis, or mixed connective tissue disease will receive ultrasound-guided injections. The main goa…
Phase: PHASE2 • Sponsor: Robyn T. Domsic, MD, MPH • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New shots aim to soothe severe eczema in major pfizer trial
Symptom relief Recruiting nowThis study tests two experimental injectable drugs (PF-07275315 and PF-07264660) for adults with moderate to severe atopic dermatitis (eczema) that hasn't improved with skin creams. About 340 participants will receive the drugs or a placebo over up to 13 months to see if the medi…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New eczema cream studied in kids and adults – could reduce steroid use?
Symptom relief Recruiting nowThis study is testing a cream called RV4421B-EV0407, a medical device already sold in some countries, for mild to moderate atopic dermatitis (eczema). It includes 105 participants from 3 months old to adults, with diverse skin types. The cream is used alone or with steroid creams…
Phase: NA • Sponsor: Pierre Fabre Dermo Cosmetique • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New pill for eczema enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new oral drug called SYX-5219 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. About 149 participants will take single or multiple doses ov…
Phase: PHASE1 • Sponsor: Sitryx Therapeutics Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can a shot help kids with eczema sleep through the night?
Symptom relief Recruiting nowThis study tests whether dupilumab (Dupixent) can improve sleep and reduce itching in 40 children aged 6-17 with moderate to severe eczema. Participants receive dupilumab for 12 weeks, and researchers measure sleep quality and itch using questionnaires and overnight sleep tests. …
Phase: PHASE4 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Black seed oil takes on steroids in ear eczema showdown
Symptom relief Recruiting nowThis study compares black seed (Nigella sativa) oil to standard steroid ear drops for treating eczema in the ear canal. 85 adults with ear eczema will use either the oil or steroid drops twice daily for 10 days. Researchers will measure changes in inflammation, itching, and pain …
Phase: NA • Sponsor: Bezmialem Vakif University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New cream plus light therapy aims to heal radiation burns in cancer patients
Symptom relief Recruiting nowThis study tests a new cream made from Prussian blue nanoparticles, combined with a special light therapy, to heal severe (grade III) radiation skin burns in head and neck cancer patients. The cream works by mopping up harmful molecules and, when activated by light, produces gent…
Phase: NA • Sponsor: West China Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
New dressing combo aims to soothe anal pain during rectal cancer radiation
Symptom relief Recruiting nowThis study tests whether a special dressing (Mepilex Lite) placed inside the anal canal, combined with a pain-relieving suppository (indomethacin), can better treat acute radiation dermatitis—painful, red, or ulcerated skin—caused by radiotherapy for rectal cancer. About 274 adul…
Phase: NA • Sponsor: Qianfoshan Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Magnetic muscle boost? new study tests PEMF for athletes
Symptom relief Recruiting nowThis study tests whether pulsed electromagnetic field (PEMF) therapy can improve sports performance and speed up recovery in athletes. Thirty active adults will receive either real or fake PEMF treatments twice a week for 8 weeks. Researchers will measure cycling power, fatigue, …
Phase: NA • Sponsor: Nanyang Technological University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Pfizer launches first human trial of experimental eczema treatment
Symptom relief Recruiting nowThis early-stage study tests an experimental drug called PF-07832837 in healthy adults and people with moderate to severe atopic dermatitis (eczema). The main goal is to check safety and how the drug moves through the body. Researchers will also look for early signs that the drug…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New shot could soothe severe eczema itch
Symptom relief Recruiting nowThis study tests an experimental drug called SM17, given as a shot under the skin, for adults with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it safely reduces skin redness, swelling, and itching. About 200 participants will receive either SM17 or a plac…
Phase: PHASE2 • Sponsor: SinoMab BioScience Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New gel could soothe painful rash from cancer treatment
Symptom relief Recruiting nowThis study tests a topical gel called HT-001 for treating skin rashes, dryness, and nail problems caused by EGFR inhibitor cancer drugs. About 152 adults on these cancer therapies will apply the gel daily for 6 weeks. The goal is to see if it reduces rash severity and improves qu…
Phase: PHASE2 • Sponsor: Hoth Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Eye drops vs laser: cheap acne redness fix tested
Symptom relief Recruiting nowThis study tests if timolol eye drops, applied as a cream, can reduce the red marks left after acne. It compares the drops to intense pulsed light (IPL) therapy in 60 people aged 12 and older. The goal is to see if a simple, low-cost option can work as well as a laser treatment.
Phase: EARLY_PHASE1 • Sponsor: Pham Ngoc Thach University of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
EATING YOUR WAY TO CLEARER SKIN? NEW STUDY TESTS DIET FOR ECZEMA
Symptom relief Recruiting nowThis study tests whether a diet low in saturated fats and rich in whole grains, fruits, and vegetables can reduce the severity of atopic dermatitis (eczema) in young adults. Researchers will track changes in skin symptoms and barrier function over two months. The goal is to see i…
Phase: NA • Sponsor: National University of Singapore • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Bone stimulator may speed up Athletes' return to sport after spine injury
Symptom relief Recruiting nowThis study tests whether adding a bone stimulator to standard care helps athletes aged 16–40 with a spine stress fracture (spondylolysis) heal faster, reduce pain, and return to sport sooner. About 48 participants will use the device alongside physical therapy. The goal is to see…
Phase: NA • Sponsor: The Methodist Hospital Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Taurine supplement may soothe radiation burns
Symptom relief Recruiting nowThis study tests whether taking taurine granules before daily radiation can reduce painful mouth sores and skin burns in 160 head and neck cancer patients. Half get taurine, half get a placebo, and researchers track side effect severity. If effective, it could offer a simple, low…
Phase: PHASE2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a Plant-Based lotion soothe eczema? small trial aims to find out
Symptom relief Recruiting nowThis study tests a moisturizing lotion made with Edelweiss extract, macadamia oil, and shea butter in 15 adults with mild-to-moderate eczema. Over 4 weeks, doctors will check skin redness, dryness, and severity, and participants will report any side effects. The goal is to see if…
Phase: NA • Sponsor: USMARI Research & Innovation Centre • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New eczema pill shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a daily pill called soquelitinib in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take either the drug or a placebo for 12 weeks, and doctors track skin improvements and side effects. The goal is to see if soquelitinib can safely red…
Phase: PHASE2 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC
-
New gel dressing aims to ease vaginal discomfort for thousands of women
Symptom relief Recruiting nowThis study is testing a new gel dressing for women with vaginal atrophy, lichen sclerosus, or similar vulvar skin conditions. About 2000 adult women will use the gel and report their symptoms and quality of life over 12 months. The goal is to see if the gel safely reduces discomf…
Phase: NA • Sponsor: Stratpharma AG • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Vitamin d boost may help psoriasis cream work better
Symptom relief Recruiting nowThis study tests whether adding daily oral vitamin D3 to a standard steroid cream can improve mild to moderate psoriasis. About 24 adults will use the cream for 4 weeks, then be split into two groups: one gets vitamin D, the other a placebo, for 12 weeks. After that, everyone rec…
Phase: EARLY_PHASE1 • Sponsor: Wright State University • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
New eczema drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive eith…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief Recruiting nowThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Phase: NA • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New laser aims to ease psoriasis and vitiligo in just 10 minutes per session
Symptom relief Recruiting nowThis study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …
Phase: NA • Sponsor: Szeged University • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Blocking blood flow to hemorrhoids: a promising new treatment?
Symptom relief Recruiting nowThis study tests a procedure called hemorrhoidal artery embolization (HAE) for people with internal hemorrhoids who have not had success with other treatments or cannot have surgery. The procedure blocks certain arteries to reduce blood flow to the hemorrhoid tissue, aiming to im…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to calm stubborn hives triggered by cold or scratching
Symptom relief Recruiting nowThis early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 …
Phase: PHASE1 • Sponsor: Granular Therapeutics Limited • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Psoriasis relief on a plate? diet trial tests wheat and dairy elimination
Symptom relief Recruiting nowThis study explores whether removing wheat and cow's milk from the diet can reduce inflammation and improve skin symptoms in people with mild-to-moderate psoriasis. 82 participants will follow either a wheat- and dairy-free diet or a control diet for 2 months, then some will be r…
Phase: NA • Sponsor: University of Palermo • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New hope for eczema sufferers: experimental drug GHZ339 enters Mid-Stage trial
Symptom relief Recruiting nowThis Phase 2 trial is testing an experimental drug called GHZ339 in 224 adults with moderate to severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo, and researchers will measure changes in eczema severity using the EASI score at 16 weeks. The…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New pill for eczema and psoriasis enters early safety testing
Symptom relief Recruiting nowThis early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through t…
Phase: PHASE1 • Sponsor: LAPIX Therapeutics Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Walking and diet may ease psoriasis and PCOS in women
Symptom relief Recruiting nowThis study looks at whether adding treadmill walking to a low-calorie diet can improve psoriasis and polycystic ovary syndrome (PCOS) in women. Forty obese women with both conditions will be split into two groups: one does diet plus walking, the other does diet only. The trial la…
Phase: NA • Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New pill shows promise for tough psoriasis cases
Symptom relief Recruiting nowThis study tests an oral medication called roflumilast in 36 adults with moderate-to-severe plaque psoriasis. Over 12 weeks, researchers will measure how much the skin improves and check for side effects. The goal is to see if this drug can help reduce symptoms like redness, scal…
Phase: PHASE2 • Sponsor: Ahmed Ibrahim • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Could a milk protein cream soothe Kids' eczema?
Symptom relief Recruiting nowThis pilot study tests whether a cream made with glycomacropeptide, a milk protein, can reduce eczema symptoms in children aged 2 to 12 with mild atopic dermatitis. Twenty children will apply either the glycomacropeptide cream or a standard moisturizer twice daily for four weeks.…
Phase: NA • Sponsor: Universidad Autónoma de Aguascalientes • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body processes the drug. About 63 participants will receive either the drug or a placebo, with d…
Phase: PHASE1 • Sponsor: Bambusa Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
New acne cream shows promise in chinese trial
Symptom relief Recruiting nowThis study tests a cream called trifarotene on Chinese people aged 9 and older with moderate acne on the face and upper body. About 561 participants will apply the cream or a placebo daily for 12 weeks. The goal is to see if the cream reduces acne lesions and improves skin appear…
Phase: PHASE3 • Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
New psoriasis pill enters early human safety trials
Symptom relief Recruiting nowThis early-stage study tests a new tablet called UA026 to see if it is safe and how the body processes it. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The study is split into four parts to check different doses and the …
Phase: PHASE1 • Sponsor: Usynova Pharmaceuticals Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Scientists probe how eczema drugs alter skin microbes
Knowledge-focused Recruiting nowThis study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Massive study aims to unlock secrets of food allergies
Knowledge-focused Recruiting nowThis study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Acne drug may leave you Nose-Blind: study investigates
Knowledge-focused Recruiting nowThis study looks at whether isotretinoin, a common acne medicine, changes how well people can smell. Researchers will test the sense of smell in 54 adults before and after at least 4 weeks of treatment. The goal is to understand if the drug's drying effect on the nose can reduce …
Phase: NA • Sponsor: Uşak University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive teen eczema registry launches to uncover disease patterns
Knowledge-focused Recruiting nowThis observational registry will follow 1,500 adolescents aged 12–15 with moderate-to-severe atopic dermatitis (eczema) across North America and Europe. Researchers aim to document the disease's natural history, how it's managed, and long-term outcomes. Participants will be under…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of muscle inflammation
Knowledge-focused Recruiting nowThis study aims to collect medical information and tissue samples from 500 people with suspected or confirmed inflammatory muscle diseases, as well as healthy volunteers. Researchers will use blood, muscle, and skin samples to study what causes these diseases and how they progres…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to end false food allergy diagnoses in eczema patients
Knowledge-focused Recruiting nowThis study looks at 200 people aged 3–21 with eczema and high IgE levels who may have milk or peanut allergies. Researchers will use oral food challenges to find better ways to predict true allergies. The goal is to make allergy tests more accurate and reduce unnecessary food res…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Eczema registry aims to map Real-World treatment journeys
Knowledge-focused Recruiting nowThis study is a registry that will follow 1,000 adults and teens with atopic dermatitis (eczema) who are starting or switching systemic treatments. Researchers will track which treatments people use, how long they take them, and why they change or stop. The goal is to better unde…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Scientists dig into skin bugs to unlock eczema secrets
Knowledge-focused Recruiting nowThis study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Worldwide eczema study aims to uncover disparities in care
Knowledge-focused Recruiting nowThis international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Psoriasis patients sought for Diet-and-Scan study
Knowledge-focused Recruiting nowThis study will use a new, more sensitive total-body PET scanner to measure inflammation in the skin, joints, and blood vessels of people with psoriasis. Researchers want to see if switching from a typical Western diet to a more balanced diet for 6 weeks can reduce that inflammat…
Phase: NA • Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
2500 psoriasis patients enrolled to see how new treatments work in real life
Knowledge-focused Recruiting nowThis study follows 2500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will check their progress at 16 and 24 weeks using questionnaires. The goal is to build a detailed picture of early treatment responses in real-world setti…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Could your environment trigger this rare muscle disease?
Knowledge-focused Recruiting nowThis study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Eczema flare predictor device tested in new study
Knowledge-focused Recruiting nowThis study is testing a handheld device called Nevisense Go to see if it can predict eczema (atopic dermatitis) flares before they become visible or cause symptoms. About 450 people aged 12 to 89 with a history of eczema flares will use the device at home for 90 days. The goal is…
Sponsor: Castle Biosciences Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Eczema breakthrough? DNA in blood could predict Flare-Ups
Knowledge-focused Recruiting nowThis study looks at whether tiny DNA fragments released from damaged skin cells into the blood can help measure eczema severity. Researchers will compare blood and skin samples from 80 adults with eczema and healthy volunteers. The goal is to understand how these DNA fragments tr…
Sponsor: Zhongda Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive eye gene bank aims to unlock secrets of rare blindness
Knowledge-focused Recruiting nowThis study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Scientists hunt for bacterial clues in vitiligo patients
Knowledge-focused Recruiting nowThis study looks at the bacteria living on the skin and in the gut of 100 adults with and without vitiligo. Researchers want to see if people with active or stable vitiligo have different bacteria compared to healthy volunteers. No treatments or drugs are given—just samples colle…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
World's largest psoriasis care study launches to uncover treatment gaps
Knowledge-focused Recruiting nowThis study observes how people with psoriasis receive care in different countries. Researchers will collect data from routine doctor visits to understand treatment patterns, disease severity, and quality of life. The goal is to identify gaps in healthcare delivery and improve out…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Tiny study aims to unlock why dupilumab works for eczema
Knowledge-focused Recruiting nowThis study looks at how dupilumab, an approved eczema drug, changes immune cells in the skin. Researchers will take skin samples from 15 adults with moderate-to-severe eczema before and after treatment. The goal is to understand the molecular changes that lead to improvement, not…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
NIH launches major study to unlock secrets of rare inflammatory diseases
Knowledge-focused Recruiting nowThis study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New drug PG-033 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study tests the safety of a new drug called PG-033 in 52 healthy adults aged 18 to 45. Participants receive either a single dose of PG-033 or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if a high-…
Phase: PHASE1 • Sponsor: Prime Gene Therapeutics Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Eczema itch mystery: why a gentle touch can drive you crazy
Knowledge-focused Recruiting nowThis study looks at a condition called alloknesia, where light touch—like from clothing or a breeze—triggers itching. Researchers want to find out how common this is in people with atopic dermatitis (eczema) and how it affects their daily lives. About 160 adults with eczema will …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists dig into skin healing mysteries in immune disorders
Knowledge-focused Recruiting nowThis study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study monitors how fast psoriasis drugs work in daily life
Knowledge-focused Recruiting nowThis study follows 2,500 adults with moderate-to-severe plaque psoriasis who are starting a new advanced therapy. Researchers will collect data at the start and after 2, 4, and 16 weeks to see how quickly the treatment works. The goal is to build a detailed picture of early treat…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists dig into immune signals to unlock psoriasis mystery
Knowledge-focused Recruiting nowThis study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
600 eczema patients to be watched in french Real-World treatment study
Knowledge-focused Recruiting nowThis study will follow 600 adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already taking systemic medications. Researchers will track which treatments are used, how long patients stay on them, and how well they follow their regimen. The goal is …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New tool aims to help melanoma patients with autoimmune conditions navigate treatment decisions
Knowledge-focused Recruiting nowThis study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Gene clue to worse eczema uncovered in new study
Knowledge-focused Recruiting nowThis study looks at whether a specific genetic change (IL-4Ra R576) is linked to more severe eczema. Researchers will measure skin symptoms, immune markers, and skin bacteria in 111 people aged 6 to 65 with atopic dermatitis. No new treatment is being tested; the goal is to bette…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Female athlete study: hormones may change strength and hydration
Knowledge-focused Recruiting nowThis study looks at how natural menstrual cycles and birth control pills affect strength, hydration, and energy balance in 40 female athletes. Researchers will measure muscle strength, body water, and energy use at different times of the month. The goal is to better understand ho…
Sponsor: Faculdade de Motricidade Humana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
300 patients tracked to uncover hidden cancer risks in common mouth condition
Knowledge-focused Recruiting nowThis study follows 300 people with oral lichen planus (a chronic mouth condition) for at least 6 months to see how often it turns into oral cancer. Researchers will also look for patterns and risk factors that might predict this change. No new treatments are tested—the goal is si…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Real-World data: does takhzyro stop HAE swelling in saudi patients?
Knowledge-focused Recruiting nowThis study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who took Takhzyro (lanadelumab) to prevent attacks. Researchers want to see if the drug reduces HAE activity and improves quality of life after 6 to 12 months. No new treatments…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Scientists probe hidden clot risks in autoimmune skin disorders
Knowledge-focused Recruiting nowThis study looks at blood clotting in people with autoimmune skin diseases like bullous pemphigoid and lupus. Researchers will collect blood samples from 39 participants—some with active disease and some with mild or controlled disease—plus 15 healthy controls. They will measure …
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Can shedding pounds calm psoriatic arthritis? new study investigates
Knowledge-focused Recruiting nowThis study looks at how weight loss (using tirzepatide) and a biologic drug (ixekizumab) affect the body in people with psoriatic arthritis who are overweight or obese. About 45 adults will receive one or both treatments. Researchers will take samples of skin, joint tissue, and f…
Phase: NA • Sponsor: NHS Greater Glasgow and Clyde • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New skin scanner could reveal hidden changes in eczema treatment
Knowledge-focused Recruiting nowThis study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…
Sponsor: Hôpitaux Drôme Nord • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Botox injections tested for eczema insights in tiny pilot study
Knowledge-focused Recruiting nowThis pilot study is testing whether Botox injections can change how skin cells behave in people with mild-to-moderate eczema. Eight adults will receive small doses of Botox into their eczema patches. Researchers will measure changes in eczema severity and analyze skin biopsies to…
Phase: PHASE1 • Sponsor: Daniel Kaplan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive biobank launches to unlock secrets of chronic inflammation
Knowledge-focused Recruiting nowThis study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists investigate skin microbiome in rare lymphoma
Knowledge-focused Recruiting nowThis study looks at the bacteria living on the skin of people with cutaneous T cell lymphoma, a rare type of skin cancer. Researchers will compare these bacteria to those on healthy people and people with other skin conditions like psoriasis. The goal is to understand if certain …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Scientists hunt for eye disease clues in your tears
Knowledge-focused Recruiting nowThis study collects tear samples from 300 people with dry eye, infectious keratoconjunctivitis, mucous membrane pemphigoid, or allergic conjunctivitis. Researchers will analyze the proteins and metabolites in tears to create a unique fingerprint for each condition. The goal is to…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New pill for chronic hives enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…
Phase: PHASE1 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists investigate key immune cells in severe drug allergy
Knowledge-focused Recruiting nowThis study aims to understand how a type of white blood cell called eosinophils contributes to DRESS syndrome, a severe and potentially life-threatening drug allergy. Researchers will compare blood and skin samples from 80 adults with DRESS, other drug rashes, and healthy volunte…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Acne pills may reshape your gut and skin bacteria
Knowledge-focused Recruiting nowThis study looks at how two common acne antibiotics, sarecycline and doxycycline, change the bacteria living in your gut and on your skin. Researchers will track these changes in 30 people with acne over the treatment period. The goal is to understand which antibiotic is gentler …
Phase: PHASE4 • Sponsor: Integrative Skin Science and Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Shingrix vaccine under the microscope: can it shield patients on Immune-Weakening drugs?
Knowledge-focused Recruiting nowThis study looks at how the Shingrix vaccine (for shingles) works in people with psoriasis or myelofibrosis who are taking drugs that weaken their immune system. Researchers will compare their immune response to that of similar patients not on these drugs. The goal is to understa…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study tracks dupilumab for chronic hives in Real-World settings
Knowledge-focused Recruiting nowThis study watches 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers collect information from medical records and patient surveys to see how the drug works in real life, its safety, and how it affects qual…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Mali allergy study seeks clues in gut and skin germs
Knowledge-focused Recruiting nowThis study examines how germs living on and in the body, along with environmental factors like pollution, may influence allergic diseases such as asthma and eczema in people living in Mali. Researchers will collect samples and health information from 288 participants, both with a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New french study aims to unlock secrets of severe acne
Knowledge-focused Recruiting nowThis study is creating a group of 200 acne patients at Nantes University Hospital to learn more about the disease. Researchers will track factors like acne severity, quality of life, and treatment costs, and collect skin samples. The goal is to better understand what makes acne w…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists probe blood vessel role in skin disorders
Knowledge-focused Recruiting nowThis study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists probe skin secrets to unlock eczema mysteries
Knowledge-focused Recruiting nowThis study aims to better understand chronic hand eczema and atopic dermatitis by using gentle skin tape strips and imaging to analyze skin changes and genetic activity. Researchers will compare people with these skin conditions to healthy volunteers. The goal is to identify what…
Sponsor: Dr. Robert Bissonnette • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Massive study aims to crack the code on Kids' medications
Knowledge-focused Recruiting nowThis study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New eczema registry aims to improve treatment research
Knowledge-focused Recruiting nowThis study is creating a database of children and young adults with eczema who have used or will start systemic (whole-body) treatments. Researchers will track how well these treatments work using doctor and patient reports. The goal is to make it easier to recruit for future stu…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Oxygen therapy under scrutiny: could it harm cancer Survivors' DNA?
Knowledge-focused Recruiting nowThis study looks at whether repeated sessions of hyperbaric oxygen therapy (HBOT) can damage DNA in people who have had radiation for cancer. HBOT is used to help heal tissues damaged by radiation, but it also creates reactive oxygen molecules that might harm DNA. Researchers wil…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Tiny study aims to uncover psoriasis gene clues
Knowledge-focused Recruiting nowThis study looks at inflammatory genes in people with psoriasis to better understand the disease. Researchers will take skin samples from 13 adults with psoriasis and measure genes linked to inflammation. The goal is to find markers that could help manage psoriasis in the future.
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a simple feedback trick boost athlete performance instantly?
Knowledge-focused Recruiting nowThis study looks at whether giving athletes real-time feedback during shoulder exercises helps them generate more force and do it faster. Twenty healthy, active adults will train their shoulder muscles with and without feedback to see if it makes a difference. The goal is to unde…
Phase: NA • Sponsor: Elif Turgut • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Does cannabis mess with your sleep and light sensitivity? new study aims to find out.
Knowledge-focused Recruiting nowThis study looks at how cannabis use and stopping it affect sleep, daily body rhythms, and sensitivity to light in healthy young adults aged 18-25. Researchers will compare regular cannabis users with non-users using sleep monitors, light tests, and pupil measurements. The goal i…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Psoriasis treatment gets personal: study aims to end Trial-and-Error
Knowledge-focused Recruiting nowThis study looks for gene markers that could predict how well a person with psoriasis will respond to certain FDA-approved drugs. About 56 participants will try two different psoriasis medications for 8 weeks each, while researchers take blood and skin samples. The goal is to mak…
Phase: PHASE4 • Sponsor: University Hospitals Cleveland Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Massive new registry aims to unlock secrets of swallowing disorders
Knowledge-focused Recruiting nowThis study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Researchers track blistering skin disease to pave way for better treatments
Knowledge-focused Recruiting nowThis study looks at how severe autoimmune blistering diseases like pemphigus and bullous pemphigoid are and how they affect quality of life. Researchers will enroll 150 adults to test disease severity scales and quality-of-life questionnaires. The goal is to create better tools f…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Can exercise change how aging athletes feel pain?
Knowledge-focused Recruiting nowThis study looks at how former athletes, current master's athletes, and nonathletes (ages 35-65) experience pain and respond to moderate exercise. Participants will do strength and aerobic exercises while their pain tolerance and sensitivity are measured. The goal is to understan…
Phase: NA • Sponsor: Marquette University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists seek skin samples to unlock secrets of common rashes
Knowledge-focused Recruiting nowThis study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…
Sponsor: Innovaderm Research Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New database study aims to better understand dermatomyositis skin symptoms
Knowledge-focused Recruiting nowThis study collects information from people with dermatomyositis to better understand how the disease affects their skin and quality of life. Researchers will use a special scoring tool called CDASI to measure skin changes over time. The goal is to improve knowledge about the dis…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
5G Radiation's hidden impact on skin revealed in new trial
Knowledge-focused Recruiting nowThis study looks at how high-frequency 5G waves (27.5 GHz) affect the skin. Researchers will expose healthy volunteers and people with certain skin conditions to these waves and analyze skin cell changes using advanced techniques. The goal is to understand any biological effects,…
Phase: NA • Sponsor: Prof. Olivier Gaide, MD-PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists track prednisolone levels to improve dosing for inflammatory conditions
Knowledge-focused Recruiting nowThis pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New dermatitis drug candidate begins first human safety tests
Knowledge-focused Recruiting nowThis early-stage study tests whether a single dose of the experimental drug SHR-1894 is safe and how it moves through the body. It involves 40 healthy adults aged 18 to 45. No treatment is given; the goal is to gather safety information before testing in patients with dermatitis.
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists launch hunt for clues in autoimmune skin diseases
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Psoriasis drugs may weaken defenses against genital warts
Knowledge-focused Recruiting nowThis study examines whether biologic treatments for moderate-to-severe psoriasis increase the chance of developing or having a return of genital warts. Researchers will review past medical records and follow 600 adults for two years to compare different treatments. They will also…
Sponsor: Jonathan Krygier • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Blood samples could unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can better nutrition keep college athletes healthier? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at whether screening college athletes for low energy availability and providing personalized nutrition advice from a sports dietitian can prevent Relative Energy Deficiency in Sport (RED-S). About 300 Division III athletes at Case Western Reserve University will …
Phase: NA • Sponsor: Case Western Reserve University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Smartphone study reveals hidden toll of hereditary angioedema
Knowledge-focused Recruiting nowThis study uses smartphone surveys to track the real-life burden of hereditary angioedema (HAE) in 30 adults. Participants answer quick questions about their symptoms, mood, and daily activities every other day for 8 weeks. The goal is to capture day-to-day changes that standard …
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Simple creams might fight aging inflammation
Knowledge-focused Recruiting nowThis pilot study tests whether applying over-the-counter moisturizers (CeraVe or Vaseline) daily for 4 weeks can reduce inflammation in adults aged 70 and older with dry skin. Researchers will measure skin barrier function, blood markers of inflammation, and skin microbes. The ma…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Scientists hunt for biomarkers linking everyday toxins to allergies and illness
Knowledge-focused Recruiting nowThis study is collecting blood, urine, and breath samples from 280 adults—including those with metal allergies and healthy volunteers—to see if exposure to heavy metals and pollutants leaves distinct biological markers. Researchers will compare levels of metals, lung function, an…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients
Knowledge-focused Recruiting nowThis study looks at 320 adults who are about to start strong immune-suppressing therapy and have already had at least two COVID-19 shots. Researchers want to find out if giving a COVID-19 booster right before starting therapy or waiting six months provides better protection. Part…
Phase: PHASE3 • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Gut check: study tests if tailored microbiome tips can shield C-Section babies from eczema
Knowledge-focused Recruiting nowThis study enrolls 250 infants born by C-section to see if personalized diet and probiotic advice can improve their gut bacteria and reduce early signs of eczema. Babies provide stool samples over two years, and parents get tailored recommendations based on their baby's microbiom…
Phase: NA • Sponsor: Seeding Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Massive global study launches to measure hidden toll of skin diseases
Knowledge-focused Recruiting nowThis study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
CAR T-Cell therapy: what happens years later?
Knowledge-focused Recruiting nowThis study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New study to measure hidden toll of rare skin diseases on patients and families
Knowledge-focused Recruiting nowThis study aims to understand the full burden of 9 rare skin diseases—including physical, emotional, social, and financial challenges—on patients and their families. Researchers will use special questionnaires to track how these conditions affect daily life and care needs. About …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Psoriasis patients' response to multiple biologics under scrutiny
Knowledge-focused Recruiting nowThis study looks at how well people with psoriasis respond when they need several different biologic treatments over time. Researchers will review medical records from 366 adults treated in NHS hospitals to see if each new treatment works as well as the first. No extra visits are…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Eczema drug dupilumab under Real-World microscope: will it hold up?
Knowledge-focused Recruiting nowThis study follows 900 people aged 6 and older with atopic dermatitis (eczema) who are taking dupilumab as part of their normal care. Researchers will track symptoms, quality of life, and disease control over two years using questionnaires and checkups. The goal is to see how wel…
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
5,000 patients join Yale's quest to crack rheumatic disease mysteries
Knowledge-focused Recruiting nowThis study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
School air study aims to uncover hidden triggers for Kids' allergies
Knowledge-focused Recruiting nowThis study looks at how indoor air and dust pollutants in classrooms impact children's allergies and lung function. Researchers will monitor 100 children, comparing those with allergies to those without, using questionnaires, allergy tests, and breathing tests. The goal is to ide…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New registry aims to unlock secrets of rare skin disease GPP
Knowledge-focused Recruiting nowThis study is a registry that will follow about 200 people with generalized pustular psoriasis (GPP) across North America. Researchers want to learn more about how GPP develops, how it is managed, and what happens to patients over time. Participants will be under the care of a de…
Sponsor: CorEvitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New study tracks men with lichen sclerosus for 10 years to uncover best treatments
Knowledge-focused Recruiting nowThis observational study will follow 300 men diagnosed with lichen sclerosus, a chronic skin condition affecting the genitals, for up to 10 years. Researchers will track how well routine treatments like circumcision work, monitor for disease recurrence or complications, and asses…
Sponsor: Region Västerbotten • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Blood test may predict your fitness level
Knowledge-focused Recruiting nowThis study looks at how well a blood test can predict a person's fitness level, measured by VO₂max. Researchers will collect blood samples and fitness data from 250 healthy adults. The goal is to see if certain molecules in the blood can accurately estimate how fit someone is, an…
Sponsor: VO Health, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Massive study tracks 1,000 people to unlock secrets of eczema remission
Knowledge-focused Recruiting nowThis long-term study follows 1,000 people with eczema and related allergies, plus healthy volunteers, to see what factors help the disease go into remission. Researchers will collect medical and lifestyle data to find patterns and possible biomarkers. The goal is to better unders…
Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Massive study seeks genetic roots of allergies and immune problems
Knowledge-focused Recruiting nowThis study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Gum health linked to skin disease severity in new study
Knowledge-focused Recruiting nowThis study looks at how the severity of pemphigus vulgaris, a chronic autoimmune skin disease, relates to gum health. Researchers will examine 20 adults with confirmed PV, measuring mouth sores and gum pocket depth, and comparing these with blood antibody levels. The goal is to u…
Sponsor: Saglik Bilimleri Universitesi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Patients take the lead: rare myositis study puts your voice first
Knowledge-focused Recruiting nowThis study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are …
Sponsor: Myositis International Health & Research Collaborative Alliance Foundation • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New study tracks psoriasis Drug's Real-World impact on diverse skin types
Knowledge-focused Recruiting nowThis study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III a…
Sponsor: Chronicle Academy • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Scientists build tissue bank to unlock vasculitis mysteries
Knowledge-focused Recruiting nowThis study collects tissue samples from 1,000 people with various forms of vasculitis, a group of rare inflammatory blood vessel diseases. Researchers will analyze the samples alongside clinical data to identify genes that increase risk and to spark new ideas for diagnosis and tr…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Massive study aims to unlock secrets of brain inflammation diseases
Knowledge-focused Recruiting nowThis research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…
Sponsor: Brain Inflammation Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Scientists hunt for clues to better diagnose triggered hives
Knowledge-focused Recruiting nowThis study aims to find biological markers (biomarkers) that can help diagnose and monitor chronic induced urticaria (CIndU), a condition where specific triggers like cold or pressure cause itchy hives or swelling. Researchers will compare 40 participants—including people with CI…
Sponsor: Centre for Human Drug Research, Netherlands • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Skin biopsies shed light on rare blood vessel disease
Knowledge-focused Recruiting nowThis study looks at skin samples from 50 people with different types of vasculitis, a condition where blood vessels become inflamed. Researchers want to understand how the disease affects the skin at a molecular level. Participants must have an active skin rash related to their v…
Sponsor: Peter Merkel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Rare skin complication in dermatomyositis gets a closer look
Knowledge-focused Recruiting nowThis study aims to describe a rare condition called panniculitis (inflammation of the fat under the skin) in people with dermatomyositis. Researchers will examine 20 participants aged 1 year and older to identify unique clinical and microscopic features. The goal is to better dis…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New registry aims to unlock secrets of rare diseases
Knowledge-focused Recruiting nowThis study is creating a large database to collect information on people with rare diseases like amyloidosis, sarcoidosis, and Gaucher disease. Researchers will track patients' health over time, including their symptoms, treatments, and outcomes. The goal is to improve diagnosis …
Sponsor: Hospital Italiano de Buenos Aires • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New registry aims to unlock secrets of autoimmune disease in pregnancy
Knowledge-focused Recruiting nowThis registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Scientists probe hidden IgE variants to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study looks at different forms of IgE (a protein involved in allergic reactions) in healthy volunteers and people with conditions like severe allergies, chronic hives, mastocytosis, and immune deficiencies. Researchers aim to understand how these IgE variations relate to hea…
Sponsor: KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Fat gene clue in psoriasis puzzle
Knowledge-focused Recruiting nowThis study looks at whether a gene called vaspin, which is linked to fat tissue, plays a role in psoriasis. Researchers will compare blood samples and gene patterns from 60 people with psoriasis to see if certain gene changes are tied to more severe disease. The goal is to better…
Sponsor: Aswan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study probes why some babies develop eczema: Self-Antibodies under the microscope
Knowledge-focused Recruiting nowThis study looks at whether babies born with certain self-reactive antibodies are more likely to develop eczema. Researchers will test umbilical cord blood from 500 newborns—some with a family history of allergies or eczema, some without—and follow them for two years. The goal is…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists seek skin and blood samples to unlock secrets of rare lymphoma and common eczema
Knowledge-focused Recruiting nowThis study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research, such as studying proteins in the blood and tissue. Participants must have one of these…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Eyelid eczema in atopic dermatitis: a closer look
Knowledge-focused Recruiting nowThis study aims to find out how often adults with atopic dermatitis (eczema) have eyelid involvement. Researchers will examine 550 patients from two French hospitals using skin exams, allergy tests, and eye check-ups. The goal is to better understand this common but poorly studie…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists hunt for genetic clues in rare childhood immune disorders
Knowledge-focused Recruiting nowThis study is not a treatment trial. It aims to collect blood samples from 400 children and their relatives who have rare autoimmune or autoinflammatory diseases (like lupus or juvenile arthritis). Researchers will analyze the samples to find genetic mutations that cause these co…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Eczema patients needed for study on improving treatment habits
Knowledge-focused Recruiting nowThis study aims to understand why many people with atopic dermatitis (eczema) don't use their topical medication as prescribed, which can lead to worse symptoms and higher healthcare costs. About 30 adults and children with active dermatitis will be divided into groups to receive…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New study aims to unlock secrets of common vaginal problems
Knowledge-focused Recruiting nowThis study is creating a data bank to better understand vaginal conditions like vulvodynia, yeast infections, bacterial vaginosis, and preterm labor. Researchers will look at proteins, immune markers, and vaginal bacteria in 550 women, including healthy volunteers and those with …
Sponsor: Texas Tech University Health Sciences Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Cancer Patients' skin woes under the microscope
Knowledge-focused Recruiting nowThis study looks at how skin conditions related to cancer or cancer treatments affect the well-being of cancer patients and survivors. About 1,025 participants will fill out questionnaires about their skin condition. The goal is to better understand these effects and improve trea…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New study checks eczema drug safety for pregnant women and babies
Knowledge-focused Recruiting nowThis study follows 400 pregnant women with eczema to see if the drug abrocitinib (CIBINQO) is safe during pregnancy. Half the women take the drug, the other half do not. Researchers track birth defects and infant health up to 12 months after birth. No extra doctor visits are need…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Eczema cream safety during pregnancy under scrutiny: new study compares ruxolitinib to steroids
Knowledge-focused Recruiting nowThis study will analyze health records of over 5,600 pregnant women with atopic dermatitis (eczema) to compare infant outcomes between those who used ruxolitinib cream (Opzelura) and those who used topical corticosteroid creams. Researchers will look at rates of major birth defec…
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Pregnant women with eczema needed for safety study on common cream
Knowledge-focused Recruiting nowThis study follows about 958 pregnant women with mild to moderate eczema (atopic dermatitis) who use ruxolitinib cream (Opzelura) and compares them to similar women who do not use the cream. Researchers track birth defects and other pregnancy outcomes to see if the cream is linke…
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Do kids need automatic checkups after infection? study investigates
Knowledge-focused Recruiting nowThis study looks at whether scheduling automatic follow-up appointments after a child leaves the hospital is better than only seeing a doctor when needed. About 2,674 children hospitalized for pneumonia, urinary tract infections, skin infections, or stomach bugs will take part. T…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Rare skin and muscle disease under the microscope in guadeloupe
Knowledge-focused Recruiting nowThis study tracks 10 people in Guadeloupe with dermatomyositis, a rare autoimmune disease that affects skin and muscles. Researchers want to see how severe the disease is at diagnosis, including muscle weakness, organ problems, and cancer links. No new treatment is being tested —…
Sponsor: Centre Hospitalier Universitaire de la Guadeloupe • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
10,000 volunteers needed to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study aims to collect blood, nasal fluid, skin cells, urine, and medical data from 10,000 people aged 3 to 100 with allergies, asthma, eczema, or sinus issues. Participants will have up to 3 years of follow-up visits and questionnaires. The goal is to create a large reposito…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Liver function and psoriasis drug: a safety check
Knowledge-focused Recruiting nowThis study looks at how the body processes Hemay005 tablets in people with mild or moderate liver problems compared to those with normal liver function. The goal is to find the right dose for patients with liver issues. 24 adults with psoriasis will take a single dose and have th…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Scientists hunt for hidden links between eczema and food allergies
Knowledge-focused Recruiting nowThis study collects blood and skin samples from 200 people with eczema, food allergies, or neither. Researchers will analyze these samples to find shared genetic or biochemical signals. The goal is to better understand how these conditions are connected, which could lead to bette…
Phase: NA • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Fractal cues may restore natural gait in ACL rehab
Knowledge-focused Recruiting nowThis study compares two types of visual cues during treadmill walking in 36 athletes who had ACL reconstruction. One cue is a steady beat (isochronous), the other has natural fluctuations (fractal). The goal is to see which better restores natural walking patterns and brain activ…
Phase: NA • Sponsor: Egas Moniz - Cooperativa de Ensino Superior, CRL • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Swim faster: scientists test Warm-Up hacks for young athletes
Knowledge-focused Recruiting nowThis study looks at how different warm-up exercises affect the performance of young competitive swimmers. Fifteen athletes will try three different warm-up routines, and researchers will measure their jump height and swim times for 25, 50, and 100 meters. The goal is to find the …
Phase: NA • Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Eczema Drug's ethnic secrets revealed in new study
Knowledge-focused Recruiting nowThis study looks at how the eczema drug dupilumab works in people of different ethnic backgrounds. Researchers want to understand why Asian and African American people get eczema more often and respond differently to treatment. The study will compare 30 adults with moderate-to-se…
Phase: PHASE4 • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC